Simcere Pharmaceutical Group Ltd. (2096.HK) announced on Friday that it has entered into a research collaboration agreement with Stanford Medicine to develop a treatment for irreversible Idiopathic Pulmonary Fibrosis or IPF, a chronic lung disease of unknown origin and with no known cure.
Under the May 29 agreement, the Chinese drugmaker will fund exploratory research on a novel molecule and has an option to license the molecule globally, if the study succeeds.
The project will be led by Stanford professors Chaitan Khosla and Cui Bianxiao. Idiopathic pulmonary fibrosis has a median survival time of about three years from diagnosis and current treatments cannot reverse lung scarring.
"Highly targeted therapies for idiopathic pulmonary fibrosis have long been an urgent unmet clinical need," Professor Khosla said.
On the HKSE, shares of Simcere Pharma closed Friday's trading 4.02 percent higher at HK$10.100
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.